Join 2 text

68Ga-FAPI-46 PET’s SUVpeak was highest in patients with pancreaticobiliary cancer, sarcoma, lung cancer, and esophageal/gastrointestinal cancer.

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Data from part B of the DeFianCe study demonstrate a positive overall response rate trend with sirexatamab plus bevacizumab and chemotherapy.

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss abstracts from the 2025 ASCO Annual Meeting that may impact genitourinary cancer care.

Tumor penetration of atigotatug in fuc-GM1-positive lung, liver, and bone lesions was observed in those with extensive-stage small cell lung cancer.